Shaoming Lin1, Ruilan Chen2,3,4, Song Zhu5, Huijun Wang1, Lianfang Wang1, Jian Zou6, Jingdong Yan6, Xiangdong Zhang7, Dimitrios Farmakiotis8, Xiaojiang Tan9, Eleftherios Mylonakis10. 1. Department of Respiratory and Critical Care Medicine, Chronic Airways Disease Laboratory, Huiqiao Medical Center, Nanfang Hospital, Southern Medical University, Guangzhou, People's Republic of China. 2. Department of Intensive Care Unit, Fangcun Branch of Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, People's Republic of China. 3. The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China. 4. Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, People's Republic of China. 5. District Five, Fuda Cancer Hospital, Jinan University School of Medicine, Guangzhou, People's Republic of China. 6. Informatics Department, Nanfang Hospital, Southern Medical University, Guangzhou, People's Republic of China. 7. Southern Medical University, Guangzhou, People's Republic of China. 8. Department of Medicine, Division of Infectious Diseases, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, RI, USA. 9. Department of Respiratory and Critical Care Medicine, Chronic Airways Disease Laboratory, Huiqiao Medical Center, Nanfang Hospital, Southern Medical University, Guangzhou, People's Republic of China. txjzdk@126.com. 10. Department of Medicine, Division of Infectious Diseases, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, RI, USA. emylonakis@lifespan.org.
Abstract
BACKGROUND: Candidemia is one of the most common nosocomial bloodstream infections. Early diagnosis and antifungal treatment improve clinical outcomes in some studies but not all, with diverse data reported from different institutions. Similarly, antifungal resistance is more common in the USA than in Europe, but there is little data regarding the microbiology and clinical course of candidemia in adult patients in Asia. AIMS: (1) To capture species distribution and drug resistance rates among Candida bloodstream isolates, (2) to describe clinical features of candidemia, and (3) to identify factors associated with all-cause mortality, with emphasis on early initiation of antifungal treatment, at a large tertiary University Hospital in China. METHODS: In this single-center retrospective study, we identified all patients with candidemia, between 2008 and 2014. Demographic and clinical characteristics, microbiological information, details of antifungal therapy and clinical outcomes were collected. RESULTS: We studied 166 patients. 71 (42.8%) had cancer. Candida albicans was the most frequent species (37.3%), followed by C. parapsilosis (24.1%), C. tropicalis (22.8%), and C. glabrata (14.5%). Antifungal resistance was more frequent in non-albicans strains and especially C. glabrata. Twenty patients received inappropriate treatment with all-cause mortality of 35%. The remaining 146 patients had significantly lower mortality (21.9%, P = 0.045). Among patients who received antifungal treatment, mortality rate increased with time to appropriate antifungal therapy (AAT): 13.7%, for < 24 h, 21.1% for 24-48 h, 23.1% for > 48 h, and 32.4% among patients who received no AT (χ2 for trend P = 0.039). Initiating AAT more than 24 h after blood culture collection was an independent risk factor for mortality, after adjustment for other confounders (OR 7.1, 95% CI 1.3-39.4, P = 0.024). CONCLUSIONS: Candida albicans was the most frequent cause of candidemia at a large tertiary hospital in China, but antifungal resistance is a growing concern among non-albicans Candida species. The mortality rate of patients treated with ineffective antifungal agents based on in vitro susceptibilities was similar to that of patients who received no treatment at all, and delayed initiation of antifungal treatment was associated with increased risk of death.
BACKGROUND:Candidemia is one of the most common nosocomial bloodstream infections. Early diagnosis and antifungal treatment improve clinical outcomes in some studies but not all, with diverse data reported from different institutions. Similarly, antifungal resistance is more common in the USA than in Europe, but there is little data regarding the microbiology and clinical course of candidemia in adult patients in Asia. AIMS: (1) To capture species distribution and drug resistance rates among Candida bloodstream isolates, (2) to describe clinical features of candidemia, and (3) to identify factors associated with all-cause mortality, with emphasis on early initiation of antifungal treatment, at a large tertiary University Hospital in China. METHODS: In this single-center retrospective study, we identified all patients with candidemia, between 2008 and 2014. Demographic and clinical characteristics, microbiological information, details of antifungal therapy and clinical outcomes were collected. RESULTS: We studied 166 patients. 71 (42.8%) had cancer. Candida albicans was the most frequent species (37.3%), followed by C. parapsilosis (24.1%), C. tropicalis (22.8%), and C. glabrata (14.5%). Antifungal resistance was more frequent in non-albicans strains and especially C. glabrata. Twenty patients received inappropriate treatment with all-cause mortality of 35%. The remaining 146 patients had significantly lower mortality (21.9%, P = 0.045). Among patients who received antifungal treatment, mortality rate increased with time to appropriate antifungal therapy (AAT): 13.7%, for < 24 h, 21.1% for 24-48 h, 23.1% for > 48 h, and 32.4% among patients who received no AT (χ2 for trend P = 0.039). Initiating AAT more than 24 h after blood culture collection was an independent risk factor for mortality, after adjustment for other confounders (OR 7.1, 95% CI 1.3-39.4, P = 0.024). CONCLUSIONS:Candida albicans was the most frequent cause of candidemia at a large tertiary hospital in China, but antifungal resistance is a growing concern among non-albicans Candida species. The mortality rate of patients treated with ineffective antifungal agents based on in vitro susceptibilities was similar to that of patients who received no treatment at all, and delayed initiation of antifungal treatment was associated with increased risk of death.
Authors: Kevin W Garey; Milind Rege; Manjunath P Pai; Dana E Mingo; Katie J Suda; Robin S Turpin; David T Bearden Journal: Clin Infect Dis Date: 2006-05-16 Impact factor: 9.079
Authors: Shellee A Grim; Karen Berger; Christine Teng; Sandeep Gupta; Jennifer E Layden; William M Janda; Nina M Clark Journal: J Antimicrob Chemother Date: 2011-12-18 Impact factor: 5.790
Authors: Shelley S Magill; Jonathan R Edwards; Wendy Bamberg; Zintars G Beldavs; Ghinwa Dumyati; Marion A Kainer; Ruth Lynfield; Meghan Maloney; Laura McAllister-Hollod; Joelle Nadle; Susan M Ray; Deborah L Thompson; Lucy E Wilson; Scott K Fridkin Journal: N Engl J Med Date: 2014-03-27 Impact factor: 91.245
Authors: Snigdha Vallabhaneni; Angela A Cleveland; Monica M Farley; Lee H Harrison; William Schaffner; Zintar G Beldavs; Gordana Derado; Cau D Pham; Shawn R Lockhart; Rachel M Smith Journal: Open Forum Infect Dis Date: 2015-12-14 Impact factor: 3.835
Authors: Jorge Alberto Cortés; Anita María Montañez; Ana María Carreño-Gutiérrez; Patricia Reyes; Carlos Hernando Gómez; Angela Pescador; Beatriz Ariza; Fernando Rosso Journal: J Fungi (Basel) Date: 2021-05-31